MX354660B - Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer. - Google Patents

Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer.

Info

Publication number
MX354660B
MX354660B MX2015006755A MX2015006755A MX354660B MX 354660 B MX354660 B MX 354660B MX 2015006755 A MX2015006755 A MX 2015006755A MX 2015006755 A MX2015006755 A MX 2015006755A MX 354660 B MX354660 B MX 354660B
Authority
MX
Mexico
Prior art keywords
cells
cancer
removal
mhc class
cancer cell
Prior art date
Application number
MX2015006755A
Other languages
English (en)
Other versions
MX2015006755A (es
Inventor
Klein Christian
Knoetgen Hendrik
Schmittnaegel Martina
Umana Pablo
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2015006755A publication Critical patent/MX2015006755A/es
Publication of MX354660B publication Critical patent/MX354660B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a una proteína multifuncional, caracterizada en que comprende -exactamente un dominio que presente el antígeno, -exactamente una región Fc de anticuerpo, y -al menos un sitio de unión a antígeno, en donde el dominio que presenta el antígeno comprende en la dirección N-a C-terminal ya sea (i) un péptido que provoca una respuesta a células T, (ii) una ß2-microglobulina, y (iii) los dominios extracelulares a1, a2, y a3 de una molécula HLA-A*0201, HLA-A*1101, HLA-A*2402, HLA-A*340101, HLA-C*0304, HLA-C*0401, y HLA-C*0702, o (i) un péptido que provoca una respuesta a células T, (ii) los dominios extracelulares a1, a2, a3 de una molécula de MHC clase I seleccionada del grupo que comprende HLA-A*0201, HLA-A*1101, HLA-A*2402, HLA-A*340101, HLA-C*0304, HLA-C*0401, y HLA-C*0702 y (iii) una ß2-microglobulina, en donde el sitio de unión al antígeno se une a proteoglicano de condroitín-sulfato asociado a melanoma (MCSP).
MX2015006755A 2012-11-30 2013-11-26 Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer. MX354660B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195094 2012-11-30
PCT/EP2013/074759 WO2014083004A1 (en) 2012-11-30 2013-11-26 Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins

Publications (2)

Publication Number Publication Date
MX2015006755A MX2015006755A (es) 2016-01-15
MX354660B true MX354660B (es) 2018-03-14

Family

ID=47227715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006755A MX354660B (es) 2012-11-30 2013-11-26 Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer.

Country Status (12)

Country Link
US (2) US20160083477A1 (es)
EP (1) EP2925780B1 (es)
JP (1) JP2015537043A (es)
KR (1) KR20150088881A (es)
CN (1) CN104781279A (es)
AR (1) AR093641A1 (es)
BR (1) BR112015011111A2 (es)
CA (1) CA2887486A1 (es)
HK (1) HK1211949A1 (es)
MX (1) MX354660B (es)
RU (1) RU2015125639A (es)
WO (1) WO2014083004A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
US20170176435A1 (en) * 2014-01-21 2017-06-22 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン ｓｙｎＴａｃポリペプチド及びその使用
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
DE102017115966A1 (de) * 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019162937A1 (en) * 2018-02-20 2019-08-29 Technion Research & Development Foundation Limited Immunotherapeutic composition for the treatment of cancer
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
CN113412123A (zh) * 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU5532601A (en) * 2000-04-12 2001-10-30 Univ Rochester Targeted vaccine delivery systems
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
MX2008014722A (es) * 2006-05-19 2011-04-15 Teva Pharma Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
EP2197908A2 (en) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US9266938B2 (en) * 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
KR102038155B1 (ko) * 2011-06-22 2019-10-29 에프. 호프만-라 로슈 아게 Mhc 클래스 i 포함 복합체를 사용한 순환 바이러스-특이적 세포독성 t-세포에 의한 표적 세포의 제거
SG11201504414UA (en) * 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
AU2016275312B2 (en) * 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Also Published As

Publication number Publication date
EP2925780B1 (en) 2017-10-18
HK1211949A1 (en) 2016-06-03
WO2014083004A1 (en) 2014-06-05
BR112015011111A2 (pt) 2017-11-14
MX2015006755A (es) 2016-01-15
KR20150088881A (ko) 2015-08-03
US20190169309A1 (en) 2019-06-06
JP2015537043A (ja) 2015-12-24
RU2015125639A (ru) 2017-01-10
US20160083477A1 (en) 2016-03-24
CA2887486A1 (en) 2014-06-05
EP2925780A1 (en) 2015-10-07
CN104781279A (zh) 2015-07-15
AR093641A1 (es) 2015-06-17

Similar Documents

Publication Publication Date Title
MX354660B (es) Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer.
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
MX2013014961A (es) Variantes anticuerpos y usos de las mismas.
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
NZ602220A (en) Antibodies with ph dependent antigen binding
PH12013502499A1 (en) Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
IN2014DN03451A (es)
EA201491524A1 (ru) Связывающиеся с эритроцитами терапевтические средства
MX360741B (es) Constructos de polipéptidos y sus usos.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
MX377297B (es) Anticuerpos tem8 y su uso.
IN2014CN02906A (es)
WO2014165093A3 (en) Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX2015009502A (es) Anticuerpos que comprenden dominios constantes quimericos.
NZ713904A (en) Thrombin cleavable linker with xten and its uses thereof
HK1223303A1 (zh) 凝血酶可裂解连接子
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
UA115436C2 (uk) Протираковий злитий протеїн
WO2011108008A3 (en) Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration